FDA OK's Pierre Fabre's Hemangeol in infantile hemangioma
This article was originally published in Scrip
Executive Summary
The FDA has granted approval to French drug maker Pierre Fabre Dermatologie to market Hemangeol (propranolol hydrochloride) as a treatment for proliferating infantile hemangioma requiring systemic therapy – the first medicine to win that indication in the US.